Are you Dr. Lendvai?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 73 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-3368Fax+1 646-227-7116
Summary
- Dr. Nikoletta Lendvai, MD is a hematologist in New York, New York. She is currently licensed to practice medicine in New York and New Jersey. She is affiliated with Memorial Sloan Kettering Cancer Center and is an Instructor at Weill Cornell Medical College.
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2007
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 2001 - 2004
- Albert Einstein College of MedicineClass of 2001
Certifications & Licensure
- NJ State Medical License 2007 - 2025
- NY State Medical License 2003 - 2020
Clinical Trials
- Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 May 09
- MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 93 citationsIncidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.Adam D Cohen, Samir Parekh, Bianca D Santomasso, Jaime Gállego Pérez-Larraya, Niels W C J van de Donk
Blood Cancer Journal. 2022-02-24 - 466 citationsBelantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka
The Lancet. Oncology. 2020-02-01 - 168 citationsAntibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves
Blood Cancer Journal. 2019-03-20